AG Oetjen

Prof. Dr. med. Elke Oetjen
Clinic/Institute: Institute of Experimental Pharmacology and Toxicology
Phone: +49 (0) 40 7410 - 57252

Research Focus and Main research questions

Diabetes mellitus is increasing worldwide and is the most important risk factor for the development of cardiovascular diseases. Thus, we mainly investigate the molecular pathogenesis of this disease. Our previous work showed that the dual leucine zipper kinase (DLK, MAP3K12) becomes activated by prediabetic signals and interferes with the function of insulin producing beta-cells. We now ask whether the inhibition of this kinase prevents diabetes mellitus and aim to identify novel DLK inhibitors. In addition, we investigate the role of the transcriptional coactivator CRTC1 in the development of cardiovascular diseases.

  • Methods
  • Methods


    • Immunoblot analysis
    • immunofluorescence staining
    • reporter gene assay
    • animal experimentation

  • Publications:

    Duque Escobar J., Kutschenko A., Schröder S., Blume R., Köster K.A., Painer C., Lemcke T., Maison W., Oetjen E. (2021) Regulation of dual leucine zipper kinase activity through its interaction with calcineurin. Cell Signal 82:109953 doi:10.1016/j.cellsig.2021.109953

    Morhenn K., Quentin T., Wichmann H., Steinmetz M., Prondzynski M., Söhren K.-D., Christ T., Geertz B., Schröder S., Schöndube F.A., Hasenfuss G., Schlossarek S., Zimmermann W.H., Carrier L., Eschenhagen T., Cardinaux J.-R., Lutz S., Oetjen E. (2019) Mechanistic role of CREB regulated transcription coactivator 1 in cardiac hypertrophy. J Mol Cell Cardiol, 127:31-43; doi:10.1016/j.yjmcc.2018.12.001

    Wallbach M., Duque Escobar J., Babaeikelishomi R., Stahnke M-J., Blume R., Schröder S., Kruegel J., Maedler K., Kluth O., Kehlenbach R.H., Miosge N., Oetjen E. (2016) Distinct functions of the dual leucine zipper kinase depending on its subcellular function. Cell Signal, 28: 272- 283 Oetjen E., Lemcke T. (2016) Dual leucine zipper kinase (MAP3K12) modulators: a patent review (2010-2015). Expert Opinion on Therapeutic Patents 25:607-616 doi/full/10.1517/13543776.2016.1170810.

  • Recent Funding:

    • DFG
    • DZHK
    • Werner Otto Stiftung
    • DDG

Research Team